Isobavachin alleviates hyperuricemia-induced bone loss by GPR35-NLRP3 signal
Our findings demonstrate that GPR35 activation protects OB from HUA-induced bone loss. The GPR35 agonist IBC enhances osteogenic differentiation by modulating the GPR35-NLRP3 signaling axis, effectively attenuating bone loss in HUA. These results identify IBC as a promising novel therapeutic candidate for managing HUA-associated osteoporosis.
Authors
- Haoyu Wan
- Yanli Zhao
- Huancun Feng (ORCID: https://orcid.org/0000-0002-4880-3174)
- Denghui Xie
- Rongrong Huang (ORCID: https://orcid.org/0000-0002-9730-7898)
- Xiaobo Lu (ORCID: https://orcid.org/0000-0002-7707-7538)
- Yunjie Chen (ORCID: https://orcid.org/0000-0002-3210-6366)
- Jianxin Pang (ORCID: https://orcid.org/0000-0002-0053-2723)
- Xiaolin Cen
- Zhisheng Xiao (ORCID: https://orcid.org/0000-0001-7227-8552)
- Qun Zhang (ORCID: https://orcid.org/0000-0002-4900-0883)
- Shuqin Zhang (ORCID: https://orcid.org/0000-0002-7524-4435)
- Hong Wang (ORCID: https://orcid.org/0000-0001-9136-8959)
- Dong Ming Guo (ORCID: https://orcid.org/0000-0003-1713-9351)
- Shiqin Lin
- Suiqing Mai
- Xinzhi Liang
- Pei Zhong Zhao
Institutions
- Guangdong Pharmaceutical University (CN)
- Third Affiliated Hospital of Southern Medical University (CN)
Publication Details
- Journal
- Phytomedicine
- Published
- 2025-10-04
- DOI
- https://doi.org/10.1016/j.phymed.2025.157368
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 0.00